<p>Andrew Callos, EVP and Chief Commercial Officer of Cytokinetics Incorporated, reported a disposal of common shares of Cytokinetics Incorporated. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001061983-25-000049), on December 08, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

CYTK

<p>Andrew Callos, EVP and Chief Commercial Officer of Cytokinetics, reported the disposal of common shares of the company. The filing is available via EDGAR, the SEC's system. This information is provided by Public Technologies using AI and is not financial advice.</p>

Cytokinetics EVP and Chief Commercial Officer Andrew Callos Reports Disposal of Common Shares